Dyadic International, Inc.

You're currently holding for the Dyadic International Incorporated Second Quarter 2022 Financial Results Conference Call. At this time, we're assembling our audience and we'll be underway in just about a minute or so. We thank you for your patience in holding and ask that you please remain on the line. Thank you. Thank you. Good day and welcome to the Dyadic International Incorporated Second Quarter 2022 Financial Results Conference Call. Today's conference is being recorded. At this time, I would like to turn the conference over to Ping Rawson, the Financial Officer. Please go ahead.

Thank you. Good evening and welcome everyone to Dyadic International's Second Quarter 2022 Conference Call. I hope you have had the opportunity to review Dyadic's press release announcing financial results for the quarter ended June 30, 2022, and the recent company highlights. You may access our release and the Form 10-Q under the Investors section of the company's website at dyadic.com. On today's call, our President and CEO, Mark Emelfarb, will give a review of our second quarter 2022 business and corporate highlights. including a brief summary of our research and the business development efforts. Our Chief Business Officer, Joe Hazleton, will join Mark for the business update. I will follow with a review of our financial results in more detail. We'll then hold a brief Q&A session. At this time, I would like to inform you that certain commentary made in this conference call may be considered poor-looking statements, which involve risks and uncertainties and other factors that could cause dyadic's actual results, performance, scientific or otherwise, or achievements to be materially different from those expressed or implied by these forward-looking statements. Dyadic expressly disclaims any duty to provide updates to its forward-looking statements, whether as a result of new information, future events, or otherwise. Participants are directed to the risk factors set forth in DIATIC's report filed with ICC. It is now my pleasure to pass the call to our CEO, Mark Enosov. Mark?

Thank you, Ping. Hello, everyone, and thank you for joining DIATIC's second quarter update call. As you will hear on today's call, there's much to be excited about here at DIATIC. In Key 1, we discussed the company's intent to focus on our core business, The company now has commercial agreements in each of its three core verticals, human health, animal health, and alternative proteins. Today, I would like to discuss the progress we've made in each of these areas and how we believe that the progress will shape the future of Dyadic. At the fundamental level, Dyadic's mission is to help make protein for world health. The foundation of Dyadic is and will continue to be our science and our highly efficient microbial platforms. and the advancement of that science to create revenue, profits, long-term shareholder value, while simultaneously helping to increase access to biologic vaccines and drugs globally. The commitment to build a protein production platform to support life science manufacturing takes an unwavering belief that a potential monetary and social impact outweighs the significant investment of not just capital, but persistence, focus, and the determination to see the process through. To the many scientists we continue to work with in academia, industry, and government, our collaborators, shareholders, and board members, I want to thank you for your support during this critical journey. While, admittedly, it has been an arduous at times, as you will hear today, we are on the verge of several transformational milestones in life sciences. As we get closer to demonstrating that producing proteins using our C1 technology are safe for use in humans. Doing so will lead to our ability to open opportunities within our core verticals and capitalize on existing and new revenue opportunities for Dyadic and our collaborators. First, I would like to focus on the significant milestones we have achieved in human health. I'm proud to announce the recent submission of our first in-human clinical trial application, CTA, with the South African Health Products Regulatory Authority, SAFRA, to initiate a phase one study to support clinical safety and to demonstrate preliminary efficacy of our DYAI-100 COVID-19 recombinant protein booster vaccine. This is an important step towards establishing C1 as a safe and transformative option as a protein production platform for the development and manufacture of a growing number of biopharmaceuticals for infectious and other diseases, including oncology, arthritis, and diabetes. Our Chief Business Officer, Joe Hazelden, has been overseeing our efforts in regards to this submission. I'll now turn the call over to Joe to discuss the timing and relevant aspects of the clinical trial application, CTA for dyadic.